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Abstract: The histologic distinction between bronchioloalveolar
carcinoma and other adenocarcinomas is tissue invasion. The clin-
ical importance of lung adenocarcinoma invasion is supported by
several recent studies indicating that the risk of death in nonmuci-
nous bronchioloalveolar carcinoma is significantly lower than that of
pure invasive tumors and in tumors with greater than 0.5 cm of
fibrosis or linear invasion. Using microarray gene expression pro-
filing of human tumors, dysregulation of transforming growth fac-
tor- signaling was identified as an important mediator of tumor
invasion. Subsequent studies showed that the CC chemokine regu-
lated on activation, normal T cell expressed, and presumably se-
creted was up-regulated in invasive tumors and was required for
invasion in cells with repressed levels of the transforming growth
factor- type II receptor. Taken together, these studies illustrate how
information gained from global expression profiling of tumors can
be used to identify key pathways and genes mediating tumor growth,
invasion, and metastasis.
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The World Health Organization subclassifies adenocarci-noma (AC) based on predominant cell morphology and
growth pattern.1 The histologic distinction between bronchi-
oloalveolar carcinoma (BAC) and other ACs is tissue inva-
sion. BAC tumor cells are cuboidal to columnar, with or
without mucin, that grow in a noninvasive fashion along
alveolar walls. Invasion, defined as tumor disruption of the
alveolar basement membrane, is present in other subtypes of
AC. ACs with mixed subtypes frequently contain regions of
lepidic/noninvasive tumor at the periphery of invasive tumor.
Recent clinical reports suggest that the prognosis and
radiographic appearance of BAC is unique and may support
modifying the clinical approach to lung ACs according to
histologic subtype. Metastases to lymph nodes and extratho-
racic organs are unusual in nonmucinous BAC. The mean
5-year survival for stage I BAC and other ACs is 81 and 55%,
respectively.2 Recent reports suggest that for stage IA BAC,
limited resections rather than lobectomy, which is the current
standard resection for stage IA AC, may be curative.3 Nota-
bly, low-dose chest computed tomographic screening de-
tected lung cancer is more likely to be AC than convention-
ally detected cancer (75% versus 40%).4,5 In addition, 25% of
screen detected cancers are BAC. As a result, the identifica-
tion of invasion in screen-detected malignancy may in the
future guide a therapeutic decision of limited versus anatomic
resection.
Paralleling malignancies in other organs, such as breast
and cervix, where tumors are defined as noninvasive (in situ
carcinoma), microinvasive (microscopic invasion), or as in-
vasive carcinomas, the extent of the invasive component seen
in lung AC is associated with clinical outcomes. The clinical
importance of lung AC invasion is supported by several
recent studies,2,6–9 indicating that the risk of death in non-
mucinous BAC is significantly lower than that of pure inva-
sive tumors and in tumors with greater than 0.5 cm of fibrosis
or linear invasion. In 200 cases of small ACs (diameter 3
cm), Yokose et al.10 reported no deaths among 66 BAC cases.
In 484 cases of BAC and AC, Terasaki et al.11 reported that
lymph node involvement was absent in all BAC and was
present in 20% of ACs that had an invasive area greater than
5 mm. Similarly, among 178 patients with resected lung AC,
we found 5-year survival rates of 100 and 90% for patients
with BAC or tumors with invasive length less than 6 mm,
respectively.12 Together, these studies suggest that noninva-
sive tumors are biologically indolent and that invasion in-
creases the risk of metastatic disease and death in solitary
mixed subtype tumors.
Invasion is the first step of carcinoma metastasis, in
which epithelial cells lose cell-cell adhesion, gain motility,
and invade into adjacent stroma. Subsequent steps of metas-
tasis include vascular intravasation and extravasation, estab-
lishment of a metastatic niche, and angiogenesis.13 Tumor
invasiveness, the morphologic characteristic that distin-
guishes BAC from AC, is determined by the interaction of
tumor cells with the surrounding stroma.14,15
We16 and others17–20 have used microarray gene ex-
pression profiling of lung AC to identify signatures associated
with histology and invasion. The results of unsupervised
analyses, in which the specimens are sorted into groups in a
dendogram based on similarity of gene expression, show lung
ACs segregate into three major branches comprised predom-
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inantly of BAC, AC-mixed subtype, and pure invasive tu-
mors. These results provide biologic plausibility to support
the notion that these AC subtypes are distinct entities. Taken
together with the clinical prognostic data, these studies have
motivated efforts to reinforce the designation of purely non-
invasive tumors and to create a designation for minimally
invasive tumors in a revision of the World Health Organi-
staion lung AC classification scheme.
To identify molecular pathways important for mediat-
ing the acquisition of invasion by lung AC, we performed
supervised analysis of mRNA microarray data to identify
genes differentially expressed in noninvasive BAC and in
AC-mixed type tumors. Among the genes differentially ex-
pressed in the progression from BAC to invasive tumors was
the transforming growth factor- (TGF-) type II receptor
(TRII), which was less highly expressed by AC-mixed and
solid invasive tumors compared with BAC. This finding, which
suggested that TRII repression was required for lung AC
invasion, is supported by genetic models combining targeted
deletion of TRII with other oncogenic events such as ade-
nomatosis polyposis coli mutation in colon tumors and KRAS
mutations in pancreatic and oropharyngeal carcinomas.21–23
The phenotypes of these TGF- receptor cancer models
clearly demonstrate the importance of TGF- signaling in
tumor invasion.
TGF-, the ligand for the TGF- type II receptor is a
pleiotropic cytokine comprised of family members TGF- 1,
2, and 3 that regulate tissue homeostasis and prevent tumor
initiation by inhibiting cellular proliferation, differentiation,
and survival.24 It is secreted as a latent molecule and is
activated by cleavage by proteases and other molecules.25
Signaling primarily occurs through SMAD protein dependent
pathways whereby ligand binding to TBRII induces phos-
phorylation and activation of TGF- type I receptor (TRI).
After interaction with TRI, phosphorylated SMAD2 and
SMAD3 dissociate to form a heterotrimeric complex with
SMAD4 and translocate into the nucleus to regulate gene
transcription (Fig. 1A). TGF- signaling may also proceed
via less well-understood SMAD independent pathways
(Fig. 1B). These “noncanonical” pathways involve various
signaling cascades including Ras/ERK, Rho/ROCK, and
TAK1/MAPK and are likely to have important roles in
mediating the protumorigenic effects of TGF-.26 Depend-
ing on context, TGF- signaling may alternatively func-
tion to suppress tumor growth or to promote tumor cell
invasion and metastasis.27–30
TGF- as a Tumor Suppressor
Although recent research has focused primarily on
TGF- receptor alterations, tumors may use various mecha-
nisms anywhere along the signaling cascade to circumvent
the inhibitory effects of TGF-.31–35 Type II receptor genetic
alterations are well characterized in gastrointestinal tumors in
which 25% of colorectal carcinomas have missense mutations
associated with microsatellite instability. Animals with tar-
geted deletion of TRII in the colonic epithelium demon-
strate increased tumor progression from adenomas to invasive
carcinomas36 similar to human colorectal tumors with loss of
type II receptor.37 In breast carcinoma models, mammary
tumors in animals with targeted deletion of TRII demon-
strated increased progression and metastases.38 A recent case-
control study in human breast tumors indicated that within
breast hyperplasia specimens, the proportion of cells with
decreased type II receptor immunostaining was associated
with increased risk for the development of invasive breast
cancer.39 Multiple lung cancer cell lines, both small cell40–42
and non-small cell,43–46 demonstrate reduced expression
TGFRII. This repression is accompanied by marked reduc-
tions in TGF- mediated growth suppression which is res-
cued after restoration of the receptor. In human lung tumor
specimens, type II receptor repression is evident in approx-
imately 40% of lung ACs overall and in up to 100% of
poorly differentiated ACs.47 Mechanisms of repression
include epigenetic silencing,48 microsatellite instability,
and frameshift mutations involving the poly(A) tract.43 For
the TGF- type I receptor, mRNA repression is detectable
in non-small cell lung cancer,49 and recent studies indicate
that TRI SNP variants are associated with an increased
risk of lung cancer.50–52
TGF- as a Tumor Promoter
Several tumors, including those arising in the lung53–55
express high levels of the TGF-, which correlates with
tumor progression and clinical prognosis.34,56–60 TGF- sig-
naling promotes epithelial to mesenchymal transition, a char-
acteristic of invasive and metastatic cells,61,62 with constitu-
tive activation of TGF- or TRI leading to increased
metastases in animal models of breast cancer.63–65 Similarly,
blockade of TGF- signaling via either dominant negative
expression of SMAD3 or defective TRI leads to decreased
lung metastases.66,67 Systemic inhibition of TGF- has been
shown to suppress metastasis68–71 and TGF- overexpression
by non-small cell lung cancer specimens was found by
multivariate analysis to be an independent risk factor for
pulmonary metastasis.72
How do we reconcile these findings with those suggest-
ing TGF- is a tumor suppressor?
Context dependency in terms of cell type, tumor stage,
and mode of inhibition of TGF- signaling are important.
Other important issues are the degree of repression of TGF-
receptor levels and the stromal response to TGF- signaling
inhibition. Rojas et al.73 have shown that different levels of
repression of the TGF- receptor are associated with differ-
ences in the activation of the SMAD and MAPK pathways
such that at lower levels of TGF- receptor activation, the
protumorigenic non-SMAD signaling pathways dominate.
Yang et al. showed that targeted deletion of TRII in the
mammary epithelium promoted breast cancer metastases
through the CXCL5/CXCR2 chemokine axis mediated re-
cruitment of Gr-1/CD11b myeloid derived suppressor
cells. Increased stromal TGF- levels at the invasive front of
tumors was shown to be important for tumor progression and
for inhibition of tumor immunosurveillance.74
Chemokine Signaling in Human Tumors with
Repressed TRII Expression—CCL5
Our results in lung AC and in in vitro systems indicate
that repression of the TGF- type II receptor increases
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invasiveness. We have shown that activation of SMAD2 and
Akt are lower in TRII knockdown cells, whereas p38 acti-
vation is slightly increased.16 We expect that TGF- signal-
ing in cells with moderately reduced type II receptor levels
persists in the invasive tumors and in the knockdown cells
and that SMAD independent pathways modulate this ef-
fect.73,75 We used a tumor cell invasion system and microar-
ray analysis to identify and characterize downstream media-
tors of TGF- signaling important for lung AC invasion.16
Among potential mediators identified was the CC (or -che-
mokine) family member CCL5 (regulated on activation, nor-
mal T cell expressed, and presumably secreted [RANTES]),
which was up-regulated by invasive tumors and TRII knock-
down cells. RANTES is involved in immunoregulatory and
inflammatory processes and is secreted by T cells and other
inflammatory cells, stromal cells, as well as tumor cells and
FIGURE 1. TGF- signaling occurs primarily via SMAD dependent pathways. A, ligand binding to the TGF- type II receptor
(TRII) induces phosphorylation and activation of type I receptor (TRI), which phosphorylates and activates the receptor
complex SMAD2 and SMAD3. Dissociated SMAD2/3 forms a heterotrimeric complex with SMAD4 that translocates into the
nucleus to regulate gene transcription. B, TGF- signaling may also proceed via SMAD-independent pathways that involve
various signaling cascades including Ras/ERK, Rho/ROCK, and TAK1/MAPK. These noncanonical pathways are likely to have
important roles in mediating the protumorigenic effects of TGF-. C, The histologic distinction between bronchioloalveolar
carcinoma (BAC) and other adenocarcinomas is tissue invasion. Invasion requires loss of cell-cell adhesion, migration, mem-
brane degradation with vascular intravasation and extravasation, establishment of the metastatic niche angiogenesis and re-
cruitment of stromal elements (top panel). We have shown that repression of TGF- type II receptor in lung adenocarcinoma
cells increases invasiveness and have used microarray analyses and inhibitor studies to identify the CC chemokine RANTES as
an important mediator of lung adenocarcinoma invasion in TRII-deficient tumors. Reprinted with permission from Borczuk AC,
Toonkel RL, Powell CA. Genomics of lung cancer. Proceedings of the American Thoracic Society 2009;6:152–158. Official Journal of
the American Thoracic Society. © American Thoracic Society.81
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normal bronchial epithelium. RANTES is a ligand for che-
mokine receptors CCR1, CCR3, CCR4, and CCR5, which are
expressed on epithelial cells, macrophages, lymphocytes,
dendritic cells, and stromal cells.76–79 Inhibition of RANTES
signaling significantly abrogates tumor invasion, suggesting
that RANTES is required for invasion in TGF- type II
receptor repressed lung AC cells (Fig. 1C). The clinical
significance of this pathway is further supported by the
finding that tumor expression of RANTES and CCR5 in lung
AC is associated with patient survival.80 Small molecule
inhibitors of CCR5 may have the potential to treat and
prevent lung AC. Taken together, these studies illustrate how
information gained from global expression profiling of tu-
mors can be used to identify key pathways and genes medi-
ating tumor growth, invasion, and metastasis.
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